Authors
Latest:
Dr. Lin on Patient Eligibility for CAR T-cell Therapy in Hematologic CanersYi Lin, MD, PhD, discusses patient eligibility for CAR T-cell therapy in hematologic cancers.
Latest:
Mount Sinai Researchers Report Encouraging Immunotherapy Option for Relapsed MyelomaT-cell redirection therapy has shown to be effective in patients unresponsive to initial bispecific antibody treatment.
Latest:
Future Directions in MDSYazan Madanat, MD, and Mikkael A. Sekeres, MD, discuss future directions and novel therapeutic agents for patients with MDS.
Latest:
Dr. Gallego on the Impact of COVID-19 on Cancer Care in SpainJose Maria Mazarico Gallego, MD, discusses the impact of the COVID-19 pandemic on cancer care in Spain.
Latest:
Dr. Vasan on Advancing the Treatment of Small HER2+ Breast CancerNeil Vasan, MD, discusses advances made in the treatment of patients with small HER2-positive breast cancer.
Latest:
Dr. Vergote on the Need to Develop Novel Therapies in Endometrial CancerIgnace B. Vergote, MD, PhD, discusses the need to develop novel therapies in endometrial cancer.
Latest:
A Dynamic Treatment Landscape Emerges for Early-Stage TNBCStandard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.
Latest:
Immunotherapy and You: Checkpoint Inhibitors in Gynecologic CancersIn this sixth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, highlight the success seen with checkpoint inhibitors in gynecologic cancers, biomarkers of interest, and recent approvals in the space.
Latest:
Dr. Schram on the Efficacy of RLY-4008 in FGFR2+ CholangiocarcinomaAlison Schram, MD, discusses the efficacy and safety of RLY-4008 in patients with cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.
Latest:
Dr. Boland on Leveraging Triplet Chemo Regimens in Non-Resectable Liver-Only mCRCPatrick Boland, MD, discusses therapeutic options for patients with patients with liver-only metastatic colorectal cancer.
Latest:
Dr. Basu Roy on the Challenges of Interpreting Molecular Testing Results in Lung CancerUpal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer.
Latest:
Dr. Cluzeau on the Efficacy of APR-246/Azacitidine in TP53-Mutated MDS and AMLThomas Cluzeau, MD, PhD, discusses the response rates of a phase 2 study with APR-246 and azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.
Latest:
Optimizing Management of HR+/HER2- BC: Future Directions in CareClosing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.
Latest:
28-Gene Score May Predict Distant Metastatic Recurrence in Advanced Head and Neck CancersAlthough the ability to treat head and neck cancer has certainly improved over the years, a significant percentage of patients experience recurrent disease after initial treatment.
Latest:
Creating the In-Person Experience on a Virtual PlatformThe coronavirus disease 2019 crisis has changed all aspects of medical education but perhaps altered clinical education most dramatically.
Latest:
Dr. Brufsky on the Efficacy of Enobosarm in ER+/AR+ Breast CancerAdam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.
Latest:
Sequencing Therapy for MSI-High and MMR-Proficient Endometrial CarcinomasA discussion on the best way to sequence therapies for patients with MSI-high and MMR-proficient endometrial carcinoma.
Latest:
Clinical Trial Diversity Efforts Gain SteamNearly 30 years after National Institutes of Health sought to increase participation of minorities in clinical trials, a demographic imbalance remains.
